NCT06969755View on ClinicalTrials.gov

Biomarkers to Enhance Early Schizophrenia Treatment

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

July 30, 2030

Study Completion Date

July 30, 2030

Conditions
Schizophenia Disorder
Interventions
DRUG

aripiprazole

aripiprazole arm (titrated dose)

DRUG

risperidone

risperidone arm (titrated dose)

DRUG

clozapine

clozapine (titrated dose)

Trial Locations (1)

11004

Feinstein Institute for Medical Research, Glen Oaks

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Northwell Health

OTHER

NCT06969755 - Biomarkers to Enhance Early Schizophrenia Treatment | Biotech Hunter | Biotech Hunter